NCT00893061 2026-03-17
MNEMOSYNE
Centre Oscar Lambret
Phase 3 Completed
Clinical Trials
112 trialsNCT01602380 2026-02-27
FALCON
AstraZeneca
Phase 3 Completed
NCT02767661 2026-02-27
MECCA
Sun Yat-sen University
Phase 3 Completed
NCT07225790 2026-02-27
Emulation of the MONARCH-3 Trial Using Specialty Oncology Electronic Health Records Databases
Brigham and Women's Hospital
Completed
NCT05896566 2026-02-24
PREcoopERA
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT03079011 2025-11-18
PADA-1
UNICANCER
Phase 3 Completed
NCT06086340 2025-11-18
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
Pfizer
Completed
NCT03671330 2025-10-31
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
Novartis
Phase 2 Completed
NCT03778931 2025-09-15
EMERALD
Stemline Therapeutics, Inc.
Phase 3 Completed
NCT05549505 2025-08-29
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
Arvinas Inc.
Phase 2 Completed
NCT05635357 2025-07-28
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane/Letrozole
Brigham and Women's Hospital
Completed
NCT03099174 2025-06-24
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT00253422 2025-06-04
SoFEA
Institute of Cancer Research, United Kingdom
Phase 3 Completed
NCT03554044 2025-05-21
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
University of California, San Francisco
Phase 1 Completed
NCT02040857 2025-04-29
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03219476 2025-04-29
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
Medical College of Wisconsin
Phase 2 Completed
NCT00265759 2025-04-23
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT03691493 2025-02-17
ASPIRE
Emory University
Phase 2 Completed
NCT04294225 2025-01-28
Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer
Mayo Clinic
Phase 2 Completed
NCT01216176 2025-01-08
A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
University of Miami
Phase 1/2 Completed
NCT03839823 2024-10-09
RIGHT Choice
Novartis
Phase 2 Completed
NCT02188745 2024-07-17
POLLY
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT03272477 2024-04-17
TP-II
Palleos Healthcare GmbH
Phase 2 Completed
NCT02648477 2024-03-19
Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
City of Hope Medical Center
Phase 2 Completed
NCT00295646 2024-03-15
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
Austrian Breast & Colorectal Cancer Study Group
Phase 3 Completed
NCT02278120 2024-03-12
MONALEESA-7
Novartis
Phase 3 Completed
NCT03321981 2024-03-07
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
Merus B.V.
Phase 2 Completed
NCT01814397 2024-02-07
Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients
University of Michigan Rogel Cancer Center
Completed
NCT03481998 2023-11-21
A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Completed
NCT00066573 2023-08-25
Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT03555877 2023-07-07
AMICA
GBG Forschungs GmbH
Phase 2 Completed
NCT00921115 2023-05-19
Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.
University of Kansas Medical Center
Phase 2 Completed
NCT02894398 2023-03-13
INGE-B
iOMEDICO AG
Phase 2 Completed
NCT00128843 2023-03-06
Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients
Spanish Breast Cancer Research Group
Phase 2 Completed
NCT00301457 2023-02-21
DATA
Maastricht University Medical Center
Phase 3 Completed
NCT02753686 2023-02-15
Treat ER+ight
Novartis
Completed
NCT02440230 2022-12-30
SEAT
Shanghai Jiao Tong University School of Medicine
Phase 2 Completed
NCT03948568 2022-09-30
REaCT-RETT
Ottawa Hospital Research Institute
Phase 4 Completed
NCT01791985 2022-08-22
RADICAL
Imperial College London
Phase 1/2 Completed
NCT01989780 2022-08-04
BOOSTER
Japan Breast Cancer Research Group
Phase 2 Completed
NCT00405938 2021-11-18
Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT03768258 2021-09-05
TIBCaP
Millennium Wellness LLC
Completed
NCT00629616 2021-06-09
NIMFEA
UNICANCER
Phase 2 Completed
NCT00256217 2021-05-11
Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
University of California, Irvine
Phase 2 Completed
NCT01197170 2021-01-22
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01004744 2021-01-11
Pre-Surgical Intervention for Targeted Therapies for Breast Cancer
Columbia University
Phase NA Completed
NCT02511639 2020-12-03
MAIN-A
Istituto Oncologico Veneto IRCCS
Phase 3 Completed
NCT00570323 2020-07-28
PACT001
Baylor Breast Care Center
Phase 2 Completed
NCT02441946 2020-06-17
neoMONARCH
Eli Lilly and Company
Phase 2 Completed
NCT02291913 2020-02-17
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed